Clinical Trials Autologus Stem Cell

1.Spinal Cord Injury

Spinal cord injury is a trauma condition that can cause permanent paralysis and considered incurable. This condition can be caused by sudden trauma, such as sports/car accidents, result in dislocation and/or breakage of back bone and severing neural cells inside. So basically, there are two main tissues to be repaired in spinal cord injury, the bones and the nerves. We are collaborating with Orthopedic Department of RSUP Fatmawati to conduct a clinical application of bone marrow mesenchymal stem cells to spinal cord injured patients. In this project, we are trying multiple shots of bone marrow mesenchymal stem cells injection on site and intravenously. Results from the first two enrolled patients were promising.

                         

 

Christopher Reeve, an American actor famous for his role in Superman (1978), was discussing the potential benefits of stem cell at Massachusetts Institute of Technology, USA

Image courtesy of Mike Lin / Wikimedia Commons

Source: http://www.scienceinschool.org/

2.Stroke

Stroke ranks as the first leading cause of death in Indonesia. According to Indonesia Basic Health Research 2007 on 33 provinces, the prevalence of stroke was 8.2 per 1000 population. Ischemic stroke accounted for the majority of cases (67.1%) and hemorrhagic was 32.9%. The risk factors of stroke, including hypertension, diabetes mellitus, and dyslipidemia, are projected to be increasing due to the change on people lifestyle in this modernized era.

Conventional treatments of stroke involve the use of thrombolytics to restore blood flow or mechanical treatment to remove blood clots. However, those treatment are limited due to the therapeutic window of less than 3-6 hours post onset of stroke symptoms such that only few patients can receive the treatment. Additional therapy such as physical, occupational, and speech therapy may be needed.

ClinicalTrial.gov recorded at least 70 ongoing studies on the safety and efficacy of stem cells in stroke patients. The source of stem cells used are varied, but mostly using autologous bone marrow mesenchymal stem cells. Mesenchymal stem cells (MSCs) are  a type of adult stem cells having the ability to differentiate into multiple different cell types. It is believed that viable MSCs secrete neurotrophic factors that can protect the remaining neural cells as well as stimulating neruoregeneration. In this project, our obejctive is to evaluate the safety and efficacy of autologous bone marrow MSCs as alternative therapy for stroke.

Source: http://projectavalon.net/                            Source: stemsaveblog.com

3. MI

Our heart needs a constant supply of oxygen and nutrients delivered from blood flow inside the coronary arteries. An accumulation of cholesterol plaque on the wall of these arteries can attract platelets and induce blood clotting, so that the vessels become blocked suddenly. When this happens, a part of heart muscles lacks of oxygen and starts to die, which people experience it as a heart attack or myocardial infarction. We develop endothelial progenitor cell (EPC) therapy to induce new arterial formation (angiogenesis), so that the dying heart muscle can get back the oxygen, nutrient and get recovered. Endothelial progenitor cells are isolated from patient's peripheral blood and cultured for approximately one week before implanted back to the patients using catheterized retrograde method. Our EPCs are characterized for CD34, CD45, CD133, and KDR/VEGFR-2 protein markers. Functional assay of the EPCs shows lectin binding and LDL-uptake, as in natural EPCs.

Clinical Trials